Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3212]

New anti-cancer compound shows promise for breast cancer

New anti-cancer compound shows promise for breast cancer

Ponatinib gains marketing authorization in the European Union

Ponatinib gains marketing authorization in the European Union

New clues to obesity related liver cancer

New clues to obesity related liver cancer

Cure for young acute myeloid leukaemia patients increases six-fold since 1970s

Cure for young acute myeloid leukaemia patients increases six-fold since 1970s

Discount for ecancer members at the 2013 WIN Symposium

Discount for ecancer members at the 2013 WIN Symposium

Oral anti-cancer therapy, lenalidomide, now indicated as a treatment for patients with rare blood disease

Oral anti-cancer therapy, lenalidomide, now indicated as a treatment for patients with rare blood disease

EHA 2013: Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia and co-existing medical conditions

EHA 2013: Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic...

EHA 2013: Targeting the JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

EHA 2013: Targeting the JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

EHA 2013: Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma

EHA 2013: Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma

$EHA 2013: Pomalidomide prolongs survival in refractory myeloma patients$

EHA 2013: Pomalidomide prolongs survival in refractory myeloma patients

More from ecancer